LEFLUNOMIDE (leflunomide) by Charter Medical is (a mitochondrial enzyme involved in de novo pyrimidine synthesis) and has antiproliferative activity. Approved for rheumatoid arthritis. First approved in 2005.
Drug data last refreshed 20h ago
(a mitochondrial enzyme involved in de novo pyrimidine synthesis) and has antiproliferative activity. Several in vivo and in vitro experimental models have demonstrated an anti-inflammatory effect.
Antirheumatic Agent
A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
Bioequivalence Study of Generic Leflunomide 20 mg Film-coated Tablets and Reference Product Under Fasting Conditions
Leflunomide Treatment for IgG4-RD
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients
Leflunomide EfficAcy Response Related to Dosing Regimen in Early Rheumatoid Arthritis
Worked on LEFLUNOMIDE at Charter Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.